The role of the epithelial cell adhesion molecule EpCAM in cancer progression remains largely unclear. High expression of EpCAM in primary tumors is often associated with more aggressive phenotypes and EpCAM is the prime epithelial antigen in use to isolate circulating tumor cells (CTCs) and characterize disseminated tumor cells (DTCs). However, reduced expression of EpCAM was associated with epithelial-to-mesenchymal transition (EMT) and reports on a lack of EpCAM on CTCs emerged. These contradictory observations might reflect a context-dependent adaption of EpCAM expression during metastatic progression. To test this, EpCAM expression was monitored in esophageal cancer at different sites of early systemic disease. Although most of the primary esophageal tumors expressed high levels of EpCAM, the majority of DTCs in bone marrow lacked EpCAM. In vitro, downregulation of EpCAM expression at the plasma membrane was observed in migrating and invading cells, and was associated with a partial loss of the epithelial phenotype and with significantly decreased proliferation. Accordingly, induction of EMT through the action of TGFb resulted in substantial loss of EpCAM cell surface expression on esophageal cancer cells. Knock-down or natural loss of EpCAM recapitulated these effects as it reduced proliferation while enhancing migration and invasion of cancer cells. Importantly, expression of EpCAM on DTCs was significantly associated with the occurrence of lymph node metastases and with significantly decreased overall survival of esophageal cancer patients. We validated this observation by showing that high expression of EpCAM promoted tumor outgrowth after xenotransplantation of esophageal carcinoma cells. The present data disclose a dynamic expression of EpCAM throughout tumor progression, where EpCAM high phenotypes correlate with proliferative stages, whereas EpCAM low/negative phenotypes associated with migration, invasion and dissemination. Thus, differing expression levels of EpCAM must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells.
INTRODUCTION
The major reason for cancer-related death is the development of metastasis. 1, 2 It is therefore imperative to identify, characterize and target progenitor cells of metastases at the earliest time point possible and with the most efficient tools. In this respect, the definition and validation of markers and therapeutic approaches to diagnose and treat metastatic disease remain of utmost importance. Currently, potential metastatic progenitor cells, that is, circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are commonly identified via epithelial markers in blood and affected organs such as bone marrow and lymph nodes. This approach requires a constitutive expression of these tumorassociated epithelial markers for successful detection. Likewise, effective molecular therapies aiming at the elimination of these progenitors to prevent metastatic relapse also depend on a reliable expression of the targeted molecule. However, metastatic progression consists of several phases comprising invasion and dissemination of tumor cells, generation of micrometastases and their outgrowth to overt metastases. 3, 4 Hence, cells in these various phases have different requirements with respect to hallmarks of cancer, 5 that is, proliferation, adhesion, migration, invasion and resistance towards external influences including therapeutics. 6 Consequently, the use of selected epithelial markers to identify and target disseminated cancer cells currently disregards the potentially dynamic expression of these molecules in response to varying requirements of tumor cells and/ or to genetic changes occurring during progression.
in embryonic stem cells. [14] [15] [16] Activation of EpCAM signals is executed upon regulated intra-membrane proteolysis, which results in the release of the small intracellular, signal-transducing domain EpICD into the nucleus. 17 In conjunction with members of the Wnt signaling pathway, EpICD regulates the transcription of target genes 13 including genes involved in reprogramming differentiated cells into induced pluripotent stem cells. 16 In order to study the dynamics of EpCAM expression and its role in cancer progression, we analyzed EpCAM expression at multiple sites in early systemic cancer. As a model, we chose esophageal cancer, which is known to express EpCAM and is one of the most lethal cancers worldwide-characterized by early metastatic spread and intrinsic resistance to current systemic chemotherapies. 18 Our results demonstrate a strong variance of expression in which DTCs and migrating/invading cells downregulate EpCAM expression at the cell surface, whereas primary tumors and proliferating cells are characterized by high levels of EpCAM. Hence, EpCAM expression is not steady throughout tumor progression but rather adapts to the requirements at the various stages of disease, as EpCAM directly influences proliferation, migration and invasion.
RESULTS

EpCAM is often absent on cytokeratin-positive DTCs in esophageal cancer
EpCAM was prospectively analyzed on CK18
positive DTCs in 90 patients with esophageal cancer using an immunofluorescence double-labeling assay ( Figure 1a ). CK18
positive DTCs were detected in 38.9% (35/90) of the patients but co-expression of EpCAM was seen in 37.1% of cases only (n ¼ 13), whereas 62.9% revealed a CK18 positive /EpCAM low/negative phenotype ( Figure 1b) . A difference between hematogenously and lymphatically disseminated tumor cells was noted: while only 28.5% (6/21) of bone marrow DTCs were EpCAM high , 50% of the 14 DTC cases detected lymph nodes displayed EpCAM expression (Figure 1c ). In addition, we could compare the expression of EpCAM on 14 autologuous pairs comprised of primary tumors and their associated DTCs. This comparison revealed an absence of EpCAM on DTCs in 64% of patients with tumors displaying a high expression of EpCAM ( Figure 1d ). Finally, we could validate the high frequency of EpCAM expression in primary tumors in an independent set of esophageal cancers (n ¼ 216). Immunohistochemistry showed EpCAM expression in 63% (74/118) cases with squamous cell carcinomas (ESCC) and in 94% (92/98) of esophageal adenocarcinomas (EAC) (data not shown), demonstrating that the expression of EpCAM frequency on DTCs is markedly lower compared with primary esophageal cancers.
EpCAM expression on DTC correlates with poor survival of patients Next, we correlated EpCAM expression on DTCs with TNM classification parameters in all patients (n ¼ 90) and with overall survival in a sub-cohort comprising patients with at least 3 months of clinical follow-up (n ¼ 73) (Table 1) . Age, tumor size, locoregional metastases, resection margins and expression of EpCAM were prognostic parameters of a significantly decreased overall survival upon univariate analysis (Table 2) . In a multivariate analysis only the tumor size reached statistical significance as a prognostic factor for overall survival (Table 2) . Most importantly, 40% of patients harboring no or EpCAM low/negative DTCs remained alive within the observation period (480 months), whereas none of the patients with EpCAM high DTCs survived beyond 35 months (Figure 1e ). Expression of EpCAM on DTCs was significantly correlated with the presence of locoregional lymph node metastases in patients with a 3-months follow-up and in the whole patient cohort (Figure 1f ; data not shown), whereas it did not correlate with any other TNM parameter (Table 1 ). All patients with EpCAM high DTCs suffered from lymph node metastases (100%), whereas 42% of patients with EpCAM low/negative DTCs remained free of metastases (Figure 1f ). Hence, EpCAM was frequently absent on DTCs, but when expressed it was associated with a more aggressive phenotype and the prevalence of lymphatic metastases.
Reduction of EpCAM expression is associated with migration Data gained from DTCs and primary tumors suggested a dynamic and context-dependent expression of EpCAM in esophageal cancer patients. We hypothesized that the known oncogenic effects of the epithelial-associated protein EpCAM provide a selective advantage for successful metastasis outgrowth, whereas downregulation of EpCAM might be beneficial during migration, invasion and dissemination. As DTCs were on the verge of settling for metastasis, we thus could observe both phenotypes. To validate this hypothesis formally, we first focused on the role of EpCAM during the migration of esophageal carcinoma cells, because it represents a central process of dissemination. Kyse-30 squamous esophageal carcinoma cells were cultivated to full confluence and a scratch was applied to monolayers using a sterile pipette tip. Assessing the expression of EpCAM by immunofluorescence staining and confocal laser scanning microscopy revealed that cells in the intact monolayer and at the sharp edge of the scratch expressed EpCAM at the cell surface ( Figure 2A ), whereas actively migrating single cells apparently lost EpCAM on their cell surface and we noted a predominantly cytoplasmic staining. Cells furthest away from the initial scratch displayed lowest or absent expression of EpCAM (Figures 2B-D) . Direct involvement of EpCAM in the migratory phenotype of esophageal carcinoma was tested upon siRNA-mediated downregulation of EpCAM. After culturing Kyse-30 under restrictive conditions (0% FCS), cells were transiently transfected with control or EpCAM siRNA, resulting in an average 48% reduction of EpCAM cell surface expression (Figures 2B and C) and 85% reduction at mRNA level ( Figure 2G ). Under these restrictive conditions, proliferation of Kyse-30 cells was generally halted and unaffected by EpCAM knock-down ( Figure 2D ). A significantly faster wound closure was observed in EpCAM siRNA-treated cells compared with control siRNA-treated cells ( Figure 2E ), which translated into a threefold increased migration velocity ( Figure 2F ). This increased migration capacity of cells after EpCAM knock-down was paralleled by an increase of vimentin expression ( Figure 2G ). These data were confirmed in Kyse-520 cells expressing low levels of EpCAM, after transient knock-down with EpCAM-specific siRNA oligonucleotides (data not shown).
In order to exclude off-target effects of siRNA treatment, comparable experiments were performed with naturally occurring variants of the Kyse-520 esophageal squamous carcinoma lines, Kyse-520 high and Kyse-520 low , which express different levels of EpCAM at the cell surface (Figures 3a and b) . Interestingly, the EpCAM low phenotype was paralleled by a substantially and significantly lower proliferation rate down to 24% of EpCAM high cells (Figure 3c ). Scratch assays performed with both cell lines revealed also in these cells a significantly faster wound closure for low EpCAM-expressing Kyse-520 low cells (Figure 3d ), which translated into a 2.86-fold increased migration velocity (Figure 3e ). Under these conditions, the markers of EMT N-cadherin and vimentin were both much stronger expressed in Kyse-520 low cells (207-and 258-fold, respectively) ( Figure 3f ). Additionally, the invasive potential of Kyse-520 high and Kyse-520 low cells was addressed in three-dimensional co-culture experiments. Spheroids from primary human fibroblasts were incubated with single-cell suspensions of Kyse-520 high and Kyse-520 low cells. After 48 and 72 h, invasion of Kyse-520 cells into fibroblast spheroids was monitored upon immunohistochemical staining with cytokeratin 8-specific antibodies recognizing tumor cells. high cells rarely invaded into fibroblast spheroids and remained as an outer rim around spheroids. In contrast, Kyse-520 low cells readily and quantitatively invaded into fibroblast spheroids, demonstrating their strong migratory and invasive potential (Figure 3g ).
Cell surface expression of EpCAM is decreased upon induction of EMT Collectively, the abovementioned data revealed that a reduction of endogenous cell surface levels of EpCAM in esophageal cancer cells results in an increased migratory and invasive capacity of the cells, which was reminiscent of epithelial-to-mesenchymal transition. Therefore, the regulation of EpCAM was addressed under forced induction of EMT. In order to control our assay set-up, A549 lung carcinoma cells were treated with TGFb, a known inducer of EMT in these cells, 19 and effects on the expression of EpCAM were assessed. TGFb treatment of A549 cells induced typical morphologic changes such as cell flattening and the generation of spindle-shaped cells with protrusions ( Figure 4a ). Quantitative real-time PCR (qRT-PCR) specific for EPCAM, E-cadherin, N-cadherin, vimentin and the house-keeping gene high DTCs suffered from lymphatic metastases, whereas 42% of patients with EpCAM low/negative DTCs were free from metastases. TNM refers to the UICC classification of tumor size (T) and the presence of locoregional lymph node metastases (N) and distant metastases (M). pN0: no lymph node metastases; pN1-3: presence of lymph node metastases.
rpl13a were conducted with specific primer pairs. EPCAM and Ecadherin mRNA level were strongly reduced to 16 Figure 1c) . Furthermore, the mesenchymal (Figure 5e , right panel). Hence, a selection of EpCAM high cells from EpCAM shRNA clones was observed in vivo. Growth-promoting effects were recapitulated in these cells using siRNA-mediated knock-down of EpCAM and resulted in substantial reduction of cell numbers along with a shift to a mesenchymal phenotype (data not shown). 21, 22 which is according to many studies correlated with decreased overall survival 8, 20 including esophageal cancer. 23 Furthermore, several therapeutic strategies have been developed to target EpCAM and have been already tested in the clinic with variable success. 8, 24 However, a reduced EpCAM expression in primary cancers was also correlated to poor survival, 25, 26 was associated with EMT-like states 27 and is frequently observed in CTCs. 28, 29 Owing to these findings, EpCAM was proposed to function as both an oncogene and a tumor-suppressor gene. It was thought that this function of EpCAM is dependent on the tissue from which the cancer originated. Our present data now show that EpCAM low/negative and EpCAM high cancer cell populations occur both during esophageal cancer progression in a context-dependent manner and that both populations sustain the metastatic process (see scheme in Figure 6 ). In two-thirds of investigated cases bone marrowresident DTCs were EpCAM-negative despite their matched primary tumors displaying a high-level expression of EpCAM. Bone marrow-resident DTCs are perceived as early stages of malignant spread and can occur without any clinical signs of metastases. 4, 30 For the case of esophageal cancers, bone marrow appears to be a rather non-permissive environment because bone marrow metastases are commonly not of clinical importance in this tumor entity. 18 Thus, these data suggest a downregulation of EpCAM in cells that had detached and migrated from the primary tumor but did not yet generate overt metastases. Based on our findings, we propose that downregulation of EpCAM expression is mandatory to allow for a more quiescent and dormant state of cells required during phases of circulation and dissemination, and to foster the migration and invasion of cells into the surrounding high from three independent experiments performed in triplicates. (g) Invasion capacity of Kyse-520 EpCAM high and EpCAM low cells was assessed in a three-dimensional co-culture model. Spheroids of primary human fibroblasts were preformed in vitro and incubated with Kyse-520 EpCAM high or EpCAM low single cell suspensions. After 48 and 72 h, co-cultures were cryo-conserved and sections stained with cytokeratin 8-specific antibodies (red staining). Kyse-520 EpCAM high cells remained as a rim around fibroblast spheroids, whereas Kyse-520 EpCAM low cells quantitatively entered fibroblast spheroids. P-values: *o0.05; **o0.01; ***o0.001. locoregional lymph node metastases and a considerably shortened overall survival of patients harboring EpCAM high DTCs on the other hand. Moreover, EpCAM was more frequently expressed on DTCs detected in lymph nodes, one of the major target organs for metastasis in esophageal cancer. 31 Consequently, EpCAM may be perceived as a marker for proliferating cells of epithelial origin instead of a marker of mesenchymal cells, as postulated for the case of pancreatic cancer cells. 32 Indeed, active knock-down of EpCAM in esophageal cancer cells using siRNA under restrictive conditions induced a phenotype and morphology reminiscent of cells that have undergone EMT: reduced proliferation, increased migration and increased expression of mesenchymal markers. Interestingly, the existence of tumor cells with different characteristics and capacities also emerged for the case of tumor-initiating cells (TICs; also termed as cancer stem cells). Biddle et al. 33 reported on the existence of two subpopulations of TICs with a cell surface phenotype characterized by CD44 high / EpCAM low or CD44 high /EpCAM high . The latter cells were of epithelial phenotype and rather proliferative in nature, whereas CD44 high /EpCAM low cells were migratory and characterized by mesenchymal traits. Both cell types were capable of switching phenotypes, strongly suggesting plasticity within TIC populations and, interestingly, the expression of EpCAM but not CD44 was a phenotypically determinant of these two TIC-states. 33 Collectively, for the first time we present here a rationale for the observed correlation of EpCAM expression with switches of cellular phenotypes ( Figure 6 ). Our findings demonstrate that EpCAM is not only a marker of cellular states but rather directly influences proliferation, migration and invasion in an inducing and inhibitory manner, respectively. Furthermore, the present analysis sheds new light on the availability of the EpCAM molecule in early systemic cancer. Caution is needed with respect to CTC/DTC retrieval methods based solely on EpCAM, as they may underestimate the amount of disseminated cancer cells or even completely miss the detection of these cells. 29 However, EpCAM high DTCs correlated with the generation of lymph node metastases and with a significant reduction of overall survival in esophageal cancer patients. Therefore, therapeutic modalities aiming at the eradication of malignant DTCs would benefit from targeting EpCAM high cells in minimal residual disease.
DISCUSSION
We report here for the first time on a great heterogeneity of EpCAM expression in early systemic human esophageal cancer and can demonstrate that this is of biological significance for metastasis in this cancer. EpCAM is a prime example of a long known tumor-associated marker, whose expression and function was analyzed in depth in various stages of malignancies. 20 Despite this, the function of EpCAM in cancer is to date not completely understood. EpCAM is strongly expressed in a large number of primary carcinomas,
MATERIALS AND METHODS
Cell culture
Esophageal cancer cell lines Kyse-30 (German collection of microorganisms and cell cultures, DSMZ #ACC351) and Kyse-520 (DSMZ #ACC371) and non-small cell lung cancer cell line A549 were cultivated in RPMI 1640 with 10% FCS and 1% penicillin/streptomycin. Primary fibroblasts were kindly provided by the group of Dr Andreas Moosmann (Helmholtz Zentrum Mü nchen) and were grown in DMEM with 10% FCS and 1% penicillin/ streptomycin. All cell lines were grown in a 5% CO 2 atmosphere at 37 1C.
Cell counting and transient transfection GAPDH served as a house-keeping gene for standardization. Shown are mean relative mRNA expression level normalized to untreated cells from three independent experiments performed in triplicates with standard deviations. (f ) EpCAM cell surface expression was assessed upon flow cytometry with EpCAM-specific antibodies (black thin line) and isotype control antibody (gray thick line). Shown are representative results from three independent experiments. P-values: *o0.05; **o0.01; ***o0.001.
(5 0 -UCGUCCGUAUCAUUUCAAU-3 0 ) upon transient transfection using MATra (IBA). Cells were cultured for 72 h in standard culture medium supplemented with either 10% or 1% FCS. Cell numbers were assessed upon trypan blue exclusion assay.
Immunofluorescence double-staining for DTCs
The ethics committee of the Medical Faculty of the Heinrich-Heine University Dü sseldorf approved the study and informed consent was obtained from the patients before inclusion into the study for DTCs in bone marrow and lymph nodes. We analyzed a patient collective treated for esophageal cancer at the department of general, visceral and pediatric surgery of the University Hospital Dü sseldorf, Dü sseldorf, Germany. The patient characteristics are shown in Table 1 . Bone marrow aspirates were collected from 83 patients and lymph node preparations were obtained from 28 patients for the detection and further analysis of disseminated tumor cells. Bone marrow and lymph node preparations were carried out as previously described. 34 We stained 10 6 cells each with specific and isotype control antibodies, respectively. Before staining, the cells were treated for 5 min with 0.5% Triton X-100 (Sigma-Aldrich, Steinheim, Germany) in phosphate-buffered saline (PBS: 8.5 mM Na2HPO4, 2 mM KH2PO4, 150 mM NaCl (Invitrogen, Darmstadt, Germany) pH ¼ 7.4) for permeabilization, washed 3 Â 3 min in PBS and incubated for 20 min with 20% human AB serum (Biotest, Dreieich, Germany) in PBS. Incubation for 45 min with the murine-Ber-EP4 antibody directed against EpCAM (2 mg/ml Ber-EP4 (M0804, 256 mg/ml, DAKO, Hamburg, Germany, monoclonal-/ mouse antibody); 10% human AB serum; PBS) and then washed 3 Â 3 min in PBS. Subsequently the slides were incubated for 30 min, protected against light, with the fluorescence marked secondary antibody antimouse-Alexa488 (10 mg/ml Alexa488 (A11029, 2 mg/ml, Invitrogen); 10% human AB serum; PBS). This was followed by washing the slides 3 Â 3 min in PBS and a blocking step with 20% AB serum in PBS for 20 min. Then, the slides were incubated for 45 min with the second primary antibody against CK18 (diluted 1:100 CK18 in 10% AB serum (ab32118, Abcam, Cambridge, UK, polyclonal-/rabbit-antibody), PBS). This was followed by washing the slides 3 Â 3 min in PBS and incubating for 30 min with the second secondary antibody anti-rabbit-Cy3 Fab-fragment (diluted 1:100 Cy3 in 10% AB serum (C2306, Sigma-Aldrich, Steinheim, Germany), PBS). positive DTCs with a clear signal for EpCAM were designated as EpCAM high and all other CK18 positive DTCs as EpCAM low/negative . For primary tumor staining, slides of 4 mm thickness were cut from formalin-fixed paraffin embedded tissues and were stained by immunohistochemistry using the Vectastain ABC Mouse IgG Kit (Vector Laboratories, Burlingame, CA, USA) and the Ber-Ep4 anti-EpCAM antibody as described in. 35 The EpCAM expression level of each tumor was categorized according to standardized criteria for membranous cell staining referred to as the HercepTest, as previously described. 23, 35 Scratch assay Cells were seeded in six-well plates and cultured to a density of 80%. After 24 h cells were transfected with either an EpCAM-specific siRNA or a control siRNA. Next day, culture medium was replaced by medium without FCS and 8 h later a scratch was set with a sterile pipette tip. Cells were washed thrice with PBS and three random sections of two scratches per experimental group were marked. Pictures were taken at the indicated time points under an Axiovert 25 microscope (Zeiss, Jena, Germany) with a Samsung WB750 camera (Samsung, Schwalbach, Germany). To calculate the migration velocity, the gap area was calculated using ImageJ software.
For fluorescence staining, cells were plated on glass slides and grown to confluence before medium was changed to 0% FCS. After 16 h, a scratch was performed and after 24 h cells were washed with PBS, fixed in 3% paraformaldehyde and permeabilized with ice-cold methanol. Cells were treated with horse serum and incubated with anti-EpCAM antibody (VU1D9, Cell Signaling Technology, Frankfurt a.M., Germany, 1:500, 1 h). Cells were incubated with a biotin anti-mouse antibody and stained with an Alexa488-linked anti-biotin antibody. Cells were covered with VectaShield containing DAPI to stain nuclei. EpCAM staining was analyzed using a TCS-SP2 scanning system, a DM-IRB inverted microscope and LAS AF software (Leica, Solms, Germany).
Invasion assay
Primary human fibroblasts (3 Â 10 4 ) were plated in 96-well plates containing 50 ml 1% agarose in PBS per well to allow spheroid formation. Twenty-four hours later Kyse-520 high or Kyse-520 low cells (1 Â 10 4 ) were added as single-cell suspensions to fibroblast spheroids and invasion was allowed for 48 h and 72 h Spheroids were harvested, embedded in TissueTek and frozen in liquid nitrogen. Frozen sections of 4 mm thickness were cut on Superfrost plus slides and subjected to immunohistochemical analysis using the avidin-biotin-PO Complex method (Vectastain, Vector laboratories) according to the manufactureŕs protocol. In brief, sections were fixed for 5 min at room temperature in acetone, followed by incubation with fresh 3,5% paraformaldehyde for additional 5 min at room temperature. Endogenous peroxidase activity was blocked using 0.03% H 2 O 2 in PBS for 10 min, followed by overnight incubation at 4 1C with CK8 1E8-specific antibody (Covance Inc., Princeton, NJ, USA). Thereafter, sequential incubations with biotinylated anti mouse secondary antibody were applied followed by a peroxidase-labeled avidin-biotin complex (Vector Lab. Inc.). Amino-ethyl-carbazole (AEC) peroxidase substrate was used for the detection of antigen/antibody complexes, generating a redbrown staining. Counterstaining was achieved with hematoxylin (blue).
TGFb treatment
Cells were plated in six-well plates (0.5 Â 10 5 cells/well). TGF 1 (SigmaAldrich) was added (10 ng/ml) for additional 72 h. Cell surface expression of EpCAM was detected by flow cytometry. EpCAM, E-cadherin, N-cadherin and Vimentin mRNA levels were additionally measured by qRT-PCR.
Viral transduction
For stable transduction, lentiviral pGIPZ vectors V2LHS_17672 (negative control), V2LHS_134160 (EpCAM I) and V2LHS_235265 (EpCAM II) (Open Biosystems) were used. HEK293FT cells were transiently transfected with viral vector, pLP/VSVG vector (Invitrogen) and psPAX2 vector (Tronolab, Lausanne, Switzerland) with the help of the CaPO 4 method. Viral production and transduction were examined as previously described. 36 Quantitative real-time PCR Total mRNA was prepared using RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse-transcribed with the QuantiTect Reverse Transcription-Kit (Qiagen). cDNA was amplified using SYBR-Green PCR mastermix (Qiagen) and gene-specific primers in LightCycler 1.5 instrument (Roche, Mannheim, Germany) or LightCycler 480 (Roche). Normalizations across samples were performed using geometric average of constitutive gene expression of GAPDH, RPL13a or TATA-box binding protein (TBP 6 cells in 100 ml medium and 100 ml Growth Factor Reduced BD Matrigel Matrix; BD Biosciences, Heidelberg, Germany) were injected in the right (control shRNA) and the left (EpCAM-specific shRNA) flank of 6-8-week-old NOD/SCID mice (n ¼ 5). Objective quantitative endpoints were a tumor size larger than 20 mm, a tumor weight superior to 4 g and an animal weight loss superior to 20% of the body weight. According to these endpoints but no later than 28 days mice were killed by isofluran inhalation, tumor weight was assessed using a precision scale and tumor tissues were frozen for immunohistochemical analyses.
Sorted Kyse-520 cells (2,5 Â 10 5 cells in 100 ml medium and 100 ml Growth Factor Reduced BD Matrigel Matrix (BD Biosciences) were injected subcutaneously into the right (EpCAM high ) and left (EpCAM low ) flank of 9-15-week-old, male NSG mice (n ¼ 6) under inhalation anesthesia with isoflurane (Deltaselect GmbH, Dreieich, Germany). Mice were killed after 4-5 weeks upon CO 2 and the tumor weight was determined with a precision scale.
Statistical analysis
Statistical calculations were performed using Prism5 (GraphPad Software, La Jolla, CA, USA), Microsoft Excel (Microsoft, Redmond, WA, USA) and SPSS statistical software, version 18 (IBM, Munich, Germany). The KolmogorovSmirnov test was used to investigate normal distribution of data sets. If data sets followed a Gaussian (normal) distribution, the Student's t-test was applied to calculate the statistical significance of differences between treatment groups. Significance of differences between two independent groups with a nonparametric data distribution was analyzed with the Mann-Whitney U test. Contingency tables were tested with Fisher's exact test. Log-rank test for the univariate survival analysis and a backwards coxregression model for multivariate analysis was used. For multivariate analysis variables with significant prognostic impact or a prognostic trend in the univariate analysis were included into the model. Primary end point was survival, as measured from first operation time to last follow-up or death. Data of patients who were still alive at the end of the study were censored. P-values o0.05 were considered significant. Bars and error bars in the histograms represent mean values±standard deviation (s.d.) of at least three independent experiments.
